Ocrelizumab in relapsing and primary progressive multiple sclerosis: Pharmacokinetic and pharmacodynamic analyses of OPERA I, OPERA II and ORATORIO

AIMS: Ocrelizumab is a humanized monoclonal antibody that selectively targets CD20‐positive B cells and is indicated for treatment of patients with relapsing forms of multiple sclerosis (RMS) or primary progressive multiple sclerosis (PPMS). The pharmacokinetics and pharmacodynamics of ocrelizumab i...

Descripción completa

Detalles Bibliográficos
Autores principales: Gibiansky, Ekaterina, Petry, Claire, Mercier, Francois, Günther, Andreas, Herman, Ann, Kappos, Ludwig, Hauser, Stephen, Yamamoto, Yumi, Wang, Qing, Model, Fabian, Kletzl, Heidemarie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8247316/
https://www.ncbi.nlm.nih.gov/pubmed/33202059
http://dx.doi.org/10.1111/bcp.14658

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8247316/
https://www.ncbi.nlm.nih.gov/pubmed/33202059
http://dx.doi.org/10.1111/bcp.14658

Ejemplares similares